Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind comparison of ABP 710 and infliximab in moderate to severe rheumatoid arthritis
2014-004704-29Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of infliximab-axxq in rheumatoid arthritis (RA) (2 arms), sponsored by Amgen. Primary endpoint: ACR20 response at week 22. Started Aug 2016; status: completed.
02
Drugs
infliximab-axxq
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2014-004704-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004704-29.